Use of statins after liver transplantation is associated with improved survival: results of a nationwide study.
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_9E54BA86BE04
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Use of statins after liver transplantation is associated with improved survival: results of a nationwide study.
Périodique
Alimentary pharmacology & therapeutics
Collaborateur⸱rice⸱s
Swiss Transplant Cohort Study
Contributeur⸱rice⸱s
Amico P., Axel A., Aubert J.D., Banz V., Sonja B., Beldi G., Berger C., Berishvili E., Binet I., Bochud P.Y., Branca S., Bucher H., Carrel T., Catana E., Chalandon Y., De Geest S., De Rougemont O., De Seigneux S., Dickenmann M., Dreifuss J.L., Duchosal M., Fehr T., Ferrari-Lacraz S., Franscini N., Garzoni C., Soccal P.G., Gaudet C., Golshayan D., Goossens N., Hadaya K., Halter J., Heim D., Hess C., Hillinger S., Hirsch H., Hirt P., Hofbauer G., Huynh-Do U., Immer F., Koller M., Laager M., Laesser B., Lehmann R., Leichtle A., Lovis C., Manuel O., Marti H.P., Martin P.Y., Martinelli M., McLin V., Mellac K., Merçay A., Mettler K., Mueller N., Müller A., Müller-Arndt U., Müllhaupt B., Nägeli M., Oldani G., Pascual M., Posfay-Barbe K., Rick J., Rosselet A., Rossi S., Rothlin S., Ruschitzka F., Schachtner T., Schanz U., Schaub S., Schnyder A., Schuurmans M., Sengstag T., Simonetta F., Stampf S., Steiger J., Stirniman G., Stürzinger U., Van Delden C., Venetz J.P., Villard J., Vionnet J., Wick M., Wilhlem M., Yerly P.
ISSN
1365-2036 (Electronic)
ISSN-L
0269-2813
Statut éditorial
Publié
Date de publication
10/2022
Peer-reviewed
Oui
Volume
56
Numéro
7
Pages
1194-1204
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
There is limited information on the effects of statins on the outcomes of liver transplantation (LT), regarding either their use by LT recipients or donors.
To analyse the association between statin exposure and recipient and graft survival.
We included adult LT recipients with deceased donors in a nationwide prospective database study. Using a multistate modelling approach, we examined the effect of statins on the transition hazard between LT, biliary and vascular complications and death, allowing for recurring events. The observation time was 3 years.
We included 998 (696 male, 70%, mean age 54.46 ± 11.14 years) LT recipients. 14% of donors and 19% of recipients were exposed to statins during the study period. During follow-up, 141 patients died; there were 40 re-LT and 363 complications, with 66 patients having two or more complications. Treatment with statins in the recipient was modelled as a concurrent covariate and associated with lower mortality after LT (HR = 0.35; 95% CI 0.12-0.98; p = 0.047), as well as a significant reduction of re-LT (p = 0.004). However, it was not associated with lower incidence of complications (HR = 1.25; 95% CI = 0.85-1.83; p = 0.266). Moreover, in patients developing complications, statin use was significantly associated with decreased mortality (HR = 0.10; 95% CI = 0.01-0.81; p = 0.030), and reduced recurrence of complications (HR = 0.43; 95% CI = 0.20-0.93; p = 0.032).
Statin use by LT recipients may confer a survival advantage. Statin administration should be encouraged in LT recipients when clinically indicated.
To analyse the association between statin exposure and recipient and graft survival.
We included adult LT recipients with deceased donors in a nationwide prospective database study. Using a multistate modelling approach, we examined the effect of statins on the transition hazard between LT, biliary and vascular complications and death, allowing for recurring events. The observation time was 3 years.
We included 998 (696 male, 70%, mean age 54.46 ± 11.14 years) LT recipients. 14% of donors and 19% of recipients were exposed to statins during the study period. During follow-up, 141 patients died; there were 40 re-LT and 363 complications, with 66 patients having two or more complications. Treatment with statins in the recipient was modelled as a concurrent covariate and associated with lower mortality after LT (HR = 0.35; 95% CI 0.12-0.98; p = 0.047), as well as a significant reduction of re-LT (p = 0.004). However, it was not associated with lower incidence of complications (HR = 1.25; 95% CI = 0.85-1.83; p = 0.266). Moreover, in patients developing complications, statin use was significantly associated with decreased mortality (HR = 0.10; 95% CI = 0.01-0.81; p = 0.030), and reduced recurrence of complications (HR = 0.43; 95% CI = 0.20-0.93; p = 0.032).
Statin use by LT recipients may confer a survival advantage. Statin administration should be encouraged in LT recipients when clinically indicated.
Mots-clé
Adult, Aged, Graft Survival, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Liver Transplantation, Male, Middle Aged, Retrospective Studies, Risk Factors, Treatment Outcome, cardiovascular disease, dyslipidemia, solid organ transplantation, survival
Pubmed
Web of science
Création de la notice
26/01/2024 11:35
Dernière modification de la notice
01/03/2024 8:06
Données d'usage
